// App-Quantinova.ai

2537 : A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Morten Mau-Soerensen

Principal Investigators

  • Albiruni R. A. Razak

  • Anthony Frank Shields

  • Amit M. Oza

  • Michael Kauffman

  • Lillian L. Siu

  • Philippe L. Bedard

  • Hemchandra Mahaseth

  • Mansoor Raza Mirza

  • Sharon Shacham

  • Ulrik Niels Lassen

  • Tami Rashal

  • Jennifer Cooksey

  • Yosef Landesman

  • Gregory Pond

  • Amit MahipAlNashat Y. Gabrail

  • John F. Gerecitano

Medical Centers

  • Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Karyopharm Therapeutics, Natick, MAPrincess Margaret Cancer Center, University Health Network, Toronto, ON, CanadaKaryopharm Therapeutics, Newton, MA

  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark

  • Osmosis Research Inc., Toronto, ON, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Gabrail Cancer Center, Canton, OH

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

Locations

  • United States

  • Canada

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Exportin 1

Drug/Treatment

  • Selinexor

  • KPT-330

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01607905

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved